Investigation of the antimicrobial activity of coagulase negative Staphylococci of human
origin
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Coagulase Negative Staphylococci (CoNS) are significant members of the human microbiome and have
been identified as a source of bacteriocins, small bioactive substances recognised for their antimicrobial
properties. In this study we screened a bank of 37 human derived CoNS for the production of these
peptides with emphasis on identifying those with the ability to inhibit the growth of Methicillin
Resistant Staphylococcus aureus (MRSA). Deferred antagonism assays confirmed potential
antimicrobial activity in all 37 isolates against sensitive indicator M. luteus, with nine inhibiting the
growth of at least one MRSA strain they were overlaid against. Tests performed with the acidneutralised cell free supernatant of each isolate found that a large portion of the bank could interfere
with the growth rate and biofilm forming capabilities of several representative MRSA strains. 15
shortlisted CoNS underwent whole genome sequencing, resulting in the identification four strains
possessing complete putative bacteriocin operons. Strain Staphylococcus hominis C14 became the focus
of this study and through HPLC, the bacteriocin nukacin KQU-131 was isolated from the culture. The
presence of the peptide in the purified solution was confirmed using mass spectrometry. Well diffusion
assays confirmed the peptide’s activity against MRSA, an observation not previously reported in the
literature. As three other bacteriocin operons were identified, future work will entail purifying them and
characterising their activity. The identification of natural products with clinically relevant activity is
also an import feature to note given the climbing rates of resistance in nosocomial pathogens and a
depleting antibiotic pipeline.

